Biotechnological products and process engineering

Applied Microbiology and Biotechnology

, Volume 95, Issue 6, pp 1437-1444

First online:

Prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA against Helicobacter pylori infection in a BALB/c mice model

  • Le GuoAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical UniversitySchool of Laboratory Medicine, Ningxia Medical University
  • , Kunmei LiuAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University
  • , Guangxian XuAffiliated withSchool of Laboratory Medicine, Ningxia Medical University
  • , Xiaokang LiAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University
  • , Jiajie TuAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University
  • , Feng TangAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University
  • , Yingying XingAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University
  • , Tao XiAffiliated withBiotechnology Center, School of Life Science and Technology, China Pharmaceutical University Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Epitope vaccine based on the enzyme urease of Helicobacter pylori is a promising option for prophylactic and therapeutic vaccination against H. pylori infection. In our previous study, the epitope vaccine CTB-UA, which was composed of the mucosal adjuvant cholera toxin B subunit (CTB) and an epitope (UreA183–203) from the H. pylori urease A subunit (UreA) was constructed. This particular vaccine was shown to have good immunogenicity and immunoreactivity and could induce specific neutralizing antibodies, which exhibited effectively inhibitory effects on the enzymatic activity of H. pylori urease. In this study, the prophylactic and therapeutic efficacy of the epitope vaccine CTB-UA was evaluated in a BALB/c mice model. The experimental results indicated that oral prophylactic or therapeutic immunization with CTB-UA significantly decreased H. pylori colonization compared with oral immunization with PBS. The results also revealed that the protection was correlated with antigen-specific IgG, IgA, and mucosal secretory IgA antibody responses. CTB-UA may be a promising vaccine candidate for the control of H. pylori infection.

Keywords

Epitope vaccine Helicobacter pylori Cholera toxin B subunit Urease A subunit Neutralizing antibody